科研之友
微信
新浪微博
Facebook
分享链接
摘要
Reduction of low density lipoprotein (LDL) cholesterol through statin therapy has only modestly decreased coronary heart disease (CHD) associated mortality in developed countries, which has prompted the search for alternative therapeutic strategies for CHD Major efforts are now focused on therapies that augment high-density lipoprotein (HDL) mediated reverse cholesterol transport (RCT), and ultimately increase the fecal disposal of cholesterol The process of RCT has long been thought to simply involve HDL mediated delivery of peripheral cholesterol to the liver for biliary excretion out of the body However, recent studies have revealed a novel pathway for RCT that does not rely on biliary secretion This non biliary pathway rather involves the direct excretion of cholesterol by the proximal small intestine Compared to RCT therapies that augment biliary sterol loss, modulation of non biliary fecal sterol loss through the intestine is a much more attractive therapeutic strategy, given that excessive biliary cholesterol secretion can promote gallstone formation However, we are at an early stage in understanding the molecular mechanisms regulating the non biliary pathway for RCT, and much additional work is required in order to effectively target this path way for CHD prevention The purpose of this review is to discuss our current understanding of
- 出版日期2010-12-21
